{"transactions":[{"id":741768,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:37:11.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":34843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":34843,"derivative":{"exercise_price":15.22,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":34843},"source":{"system":"sec-edgar","filing":"0001193125-26-267708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526267708/ownership.xml","form_type":"4"}},{"id":795728,"issuer":{"id":4662,"kind":"organization","name":"Avalyn Pharma Inc.","symbol":"AVLN"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-01T22:26:30.000Z","date":"2026-04-30","kind":"grant","planned":false,"acquired":true,"shares":26978,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":26978,"derivative":{"exercise_price":18,"expiration_date":"2036-04-28","underlying":"Common Stock","underlying_shares":26978},"source":{"system":"sec-edgar","filing":"0001193125-26-201860","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000119312526201860/ownership.xml","form_type":"4"}},{"id":1162510,"issuer":{"id":4757,"kind":"organization","name":"Jade Biosciences, Inc."},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-01T22:15:30.000Z","date":"2025-04-29","kind":"grant","planned":false,"acquired":true,"shares":23017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase 23,017 shares of the Issuer's common stock, which vests in full on the earlier of (i) April 29, 2026 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the recipient's continued service to the Issuer."}],"balance_after":23017,"derivative":{"exercise_price":10.14,"expiration_date":"2035-04-29","underlying":"Common Stock","underlying_shares":23017},"source":{"system":"sec-edgar","filing":"0000950170-25-062119","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798749/000095017025062119/ownership.xml","form_type":"4"}},{"id":1860648,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:25:32.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning July 8, 2023 until the option is fully vested on June 8, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":0.79,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-23-035857","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919123035857/doc4.xml","form_type":"4"}},{"id":2127206,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-02T23:08:29.000Z","date":"2022-10-31","kind":"grant","acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the \"2022 Vesting Commencement Date\") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date."}],"balance_after":170000,"derivative":{"exercise_price":3.27,"expiration_date":"2032-10-30","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001209191-22-055404","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919122055404/doc4.xml","form_type":"4"}},{"id":2270424,"issuer":{"id":5160,"kind":"organization","name":"Neurogene Inc."},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-16T22:23:50.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the total shares monthly beginning June 12, 2022 until the option is fully vested on May 12, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.07,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-029323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919122029323/doc4.xml","form_type":"4"}},{"id":2421161,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-31T22:16:32.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022."}],"balance_after":170000,"derivative":{"exercise_price":8.21,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0001209191-22-005659","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919122005659/doc4.xml","form_type":"4"}},{"id":3388718,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T23:12:48.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F4","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Lundbeck, Lundbeck LLC and Purchaser.  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the \"2019 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2019 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2019 Vesting Commencement Date."}],"balance_after":0,"derivative":{"exercise_price":14,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-19-053922","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919119053922/doc4.xml","form_type":"4"}},{"id":3388717,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-24T23:12:48.000Z","date":"2019-10-22","kind":"disposition_to_issuer","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F4","text":"On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Lundbeck, Lundbeck LLC and Purchaser.  On October 22, 2019 (the \"Effective Time\"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of April 16, 2018 (the \"2018 Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the 2018 Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2018 Vesting Commencement Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"derivative":{"exercise_price":14.55,"expiration_date":"2028-04-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-19-053922","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919119053922/doc4.xml","form_type":"4"}},{"id":3388716,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-10-24T23:12:48.000Z","date":"2019-10-22","kind":"other","acquired":false,"shares":16092,"price":18,"value":289656.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"On September 16, 2019, the Reporting Person entered into a Tender and Support (the \"Support Agreement\") with H. Lundbeck A/S (\"Lundbeck\"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck (\"Purchaser\") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the \"Tender Offer\").  On October 22, 2019, Purchaser accepted the Tender Offer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-053922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919119053922/doc4.xml","form_type":"4"}},{"id":3388715,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-10-24T23:12:48.000Z","date":"2019-10-22","kind":"grant","acquired":true,"shares":11684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 13, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 17,526 shares of Issuer's Common Stock (\"RSU\"), of which 5,842 shares had vested and the remaining 11,684 shares were to vest upon the achievement of one or more milestones or a change of control of the Issuer. The remaining shares subject to the RSU vested in full upon the Effective Time (as such term is defined in footnote 4)."}],"balance_after":16092,"source":{"system":"sec-edgar","filing":"0001209191-19-053922","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919119053922/doc4.xml","form_type":"4"}},{"id":3548754,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-04-25T22:49:27.000Z","date":"2019-04-25","kind":"sale","acquired":false,"shares":1434,"price":13.6676,"value":19599.3384,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the RSU.  The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.6676 to $13.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4."}],"balance_after":4408,"source":{"system":"sec-edgar","filing":"0001209191-19-026034","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919119026034/doc4.xml","form_type":"4"}},{"id":3548753,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2019-04-25T22:49:27.000Z","date":"2019-04-23","kind":"grant","acquired":true,"shares":5842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On August 13, 2018, the Reporting Person was granted restricted stock units which represented a contingent right to receive a maximum of 17,526 shares of Issuer's Common Stock (the \"RSU\"). Up to 5,842 shares subject to the RSU vest upon obtaining acceptance by the U.S. Food and Drug Administration (or any successor entity thereto) (the \"FDA\") of the first Biologics License Application submitted to the FDA by the Company or an affiliate seeking approval for the commercial sale and marketing of eptinezumab in the United States for review and certification by the Issuer's Compensation Committee that the achievement of such milestone had been achieved (the \"FDA Filing Milestone\") and the remaining shares subject to the RSU vest upon certain other performance criteria. On April 23, 2019, the Issuer's Compensation Committee certified that the FDA Milestone had been achieved, resulting in the vesting of 5,842 shares subject to the RSU."}],"balance_after":5842,"source":{"system":"sec-edgar","filing":"0001209191-19-026034","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919119026034/doc4.xml","form_type":"4"}},{"id":3668585,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T21:51:10.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of January 1, 2019 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":150000,"derivative":{"exercise_price":14,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-19-008591","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919119008591/doc4.xml","form_type":"4"}},{"id":3961147,"issuer":{"id":154258,"kind":"organization","name":"ALDER BIOPHARMACEUTICALS INC","symbol":"ALDR"},"owners":[{"id":39294,"kind":"person","name":"Lavelle Erin","position":1,"cik":"0001737613","reported_name":"Lavelle Erin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-04-18T21:10:01.000Z","date":"2018-04-16","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of April 16, 2018 (the \"Vesting Commencement Date\") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter, for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date."}],"balance_after":300000,"derivative":{"exercise_price":14.55,"expiration_date":"2028-04-15","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001209191-18-025410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737613/000120919118025410/doc4.xml","form_type":"4"}}]}